Health

YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine

GAITHERSBURG, Md., Oct. 31, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...

2023-10-31 20:30 1474

iba 2023: Angel Yeast brings latest baking products and solutions, empowering the China team to triumph in the iba.UIBC.Cup of Bakers

MUNICH, Oct. 31, 2023 /PRNewswire/ -- Premier global yeast company Angel Yeast (SH600298) recently presented its latest products and solutions at the iba 2023, theleading trade fair for the baking and confectionery industry, hosted from October 22 to 26 in Munich. ...

2023-10-31 20:00 3246

HOYA Vision Care Releases One-Year MiYOSMART European Study Results

Initial evidence-based findings of three-year study strongly supports MiYOSMART portfolio BANGKOK, Oct. 31, 2023 /PRNewswire/ -- HOYA Vision Care, committed to developing innovative solutions to address the growing problem of myopia progression in children, extended its research toEurope in an ...

2023-10-31 19:13 1775

Select the Right Medical-Grade TPU:ICP DAS - BMP Launches a New TPU Series at COMPAMED & IPF Japan 2023

HSINCHU, Oct. 31, 2023 /PRNewswire/ -- ICP DAS – Biomedical Polymers, Asia's first medical-grade TPU (thermoplastic polyurethane) manufacturer and supplier, will be exhibiting at COMPAMED inGermany and IPF in Japan in November and December 2023. The company proudly presents its new Arothane™ ARP-...

2023-10-31 16:38 2057

Osteopathy Australia and Exercise & Sports Science Australia express profound disappointment in the tokenistic NDIS (National Disability Insurance Scheme) review process

SYDNEY, Oct. 31, 2023 /PRNewswire/ -- Osteopathy Australia, the peak body representing osteopathic healthcare professionals and Exercise & Sports Science Australia (ESSA), the peak professional organisation representing tertiary-trained exercise and sports science practitioners, today voiced thei...

2023-10-31 15:57 1434

Biotechnology Start-Up Psylo Wins Hello Tomorrow APAC Deep Tech Competition in Singapore

SINGAPORE, Oct. 31, 2023 /PRNewswire/ -- Psylo, a biotechnology start-up pioneering the development of next-generation serotonergic agents for the treatment of central nervous system (CNS) disorders, today announced that it won the Hello Tomorrow APAC deep tech competition held inSingapore. The ...

2023-10-31 15:42 1773

Embrace Exquisite Living with Innovative Personal Care Products at the 134th Canton Fair

GUANGZHOU, China, Oct. 31, 2023 /PRNewswire/ -- At Phase 3 of the 134th Canton Fair onsite, heldbetween October 31st and November 4th, "Personal Care Products" exhibition section has been rescheduled from Phase 2 to 3, emerging as a major highlight. Spanning an expansive area of around 11,000 squ...

2023-10-31 15:17 2033

Chula's Faculty of Allied Health Sciences Promotes "46 Recipes to Train Swallowing" in Elderly and Troubled Patients

BANGKOK, Oct. 31, 2023 /PRNewswire/ -- A lecturer from the Faculty of Allied Health Sciences , Chulalongkorn University in collaboration with the Thai Dietetic Association, has developed 46 nutritious recipes for swallowing tr...

2023-10-31 10:51 2056

CStone Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma, the First Anti-PD-1/PD-L1 mAb Approved for this Indication

* Sugemalimab is the world's first anti-PD-1/PD-L1 monoclonal antibody approved for relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL) indication. * This marks sugemalimab's third indication approved in China following Stage III and IV non-small cell lung cancer (NSCLC) and the ...

2023-10-31 10:16 2262

AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery

SHANGHAI, Oct. 31, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmological, neurological and psychia...

2023-10-31 09:35 2111

SK Life Science Labs, a Subsidiary of SK Biopharmaceuticals, Presents Discovery of Oral SMARCA2 Degraders Data at 6th Annual Targeted Protein Degradation Summit

Preclinical data show SK Life Science Labs compounds have robust anti-tumor efficacy in vivo and oral leads have demonstrated potent selective degradation of SMARCA2 with selective inhibition of proliferation of SMARCA4 mutant cells KING OF PRUSSIA, Pa., Oct. 31, 2023 /PRNewswire/ -- SK Life Scie...

2023-10-31 08:00 1688

LifeSpan Vision Ventures Invests in NaNotics

NORWALK, Conn., Oct. 31, 2023 /PRNewswire/ -- LifeSpan Vision Ventures, an investment firm dedicated to longevity biotech, today announced an investment in NaNotics LLC. This preclinical-stage biopharmaceutical company is developing NaNots™, novel subtractive nanoparticles that treat disease by c...

2023-10-31 02:26 2328

Huawei's new Health Lab in Finland is Advancing Global Efforts in Health & Fitness Research

HELSINKI, Oct. 30, 2023 /PRNewswire/ -- Huawei launched a new HUAWEI Health Lab located inHelsinki, Finland. Equipped with state-of-the-art testing equipment, the laboratory serves as the research platforms for Huawei's health & fitness sector. Sized at almost 1000 square metres, the laboratory ...

2023-10-30 22:25 2418

Olight 2023 Breast Cancer Charity Campaign: Illuminating Hope with Breast Cancer Foundations Across the World

FRISCO, Texas, Oct. 30, 2023 /PRNewswire/ -- Olight, a leading mobile lighting manufacturer, successfully concludes its 2023 Breast Cancer Charity Campaign, raising$77,313.43 for breast cancer support across 13 countries, including the USA, UK, Canada, Korea, Thailand, Italy, Germany, France, Aus...

2023-10-30 21:50 2194

NCCN Expands Focus on Quality of Life and Supportive Care with New Guides for People with Cancer

National Comprehensive Cancer Network publishes free NCCN Guidelines for Patients with information on improving well-being and reducing suffering and distress for people with cancer; available atNCCN.org/patientguidelines. PLYMOUTH MEETING, Pa., Oct. 30, 2023 /PRNewswire/ -- The National Compreh...

2023-10-30 20:37 1921

New Clinical Data Point to Use of GlycoMark as Biomarker of SGLT-2 Diabetes Drug Effectiveness and Compliance

RALEIGH, N.C., Oct. 30, 2023 /PRNewswire/ -- Precision Diabetes, Inc. announces new studies that show that the GlycoMark blood test, which measures 1,5-anhydroglucitol, may be useful for evaluating short-term effectiveness and assessing patient compliance of SGLT-2 inhibitor diabetes drugs. SGLT-...

2023-10-30 20:00 1199

Rational Vaccines and Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Announce Collaboration to Develop Herpes Vaccines in China

The partnership will further therapeutic and prophylactic vaccine development for the Chinese market and beyond. WOBURN, Ma. and SHENZHEN, China, Oct. 30, 2023 /PRNewswire/ -- Rational Vaccines (RVx) and Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (MH) announced they have reached an agreemen...

2023-10-30 19:30 1573

Aquinnah Pharmaceuticals Advances Oral Small Molecule Program Targeting Alzheimer's and Other Tauopathy Diseases

New preclinical data presented at CTAD demonstrates exciting potential for a new drug approach for Alzheimer's disease, reducing brain tau pathology by ~70% CAMBRIDGE, Mass., Oct. 30, 2023 /PRNewswire/ -- Aquinnah Pharmaceuticals announced preclinical research findings for a novel therapeutic des...

2023-10-30 19:00 1338

First Patient Enrolled in Phase III Clinical Trial of Boan Biotech's Nivolumab Injection

YANTAI, China, Oct. 30, 2023 /PRNewswire/ -- Boan Biotech (6955.HK) announced today that the first patient in Phase III clinical trial of its Nivolumab Injection (BA1104) inChina has been enrolled. BA1104 is the first biosimilar to Opdivo® to undergo a Phase III study in China. Nivolumab is a mo...

2023-10-30 14:51 2191

Pretty Beauty introduces SKIN AURA® bipolar radiofrequency instrument to enhance skin's fullness and contour

HONG KONG, Oct. 30, 2023 /PRNewswire/ -- To realise the dream of perfect skin for every lady, Pretty Beauty introduces the latest SKIN AURA® bipolar radiofrequency instrument, a beauty device launched byGermany's Wellcomet Technology. This instrument's care process starts by activating the fat la...

2023-10-30 14:40 1462
1 ... 107108109110111112113 ... 580

Week's Top Stories